Neochromosome

Executive Summary

Neochromosome is a San Diego-based biotechnology company pioneering genome-scale biological engineering through its synthetic DNA and cell engineering services. Founded in 2014, the company's core technology originates from the Synthetic Yeast Genome Project (Sc2.0), positioning it at the forefront of synthetic genomics. Neochromosome enables partners to design and build custom synthetic chromosomes and organisms, with applications spanning novel therapeutics, sustainable industrial products, and advanced research tools. By leveraging its expertise in large-scale DNA synthesis and assembly, the company aims to accelerate the development of bio-based solutions across multiple industries. As a private entity with an undisclosed funding history and stage, Neochromosome operates in the rapidly evolving synthetic biology sector. Its platform addresses key challenges in biological engineering, offering end-to-end services from gene design to genome integration. The company's alignment with the Sc2.0 consortium provides credibility and access to cutting-edge techniques. While the market for synthetic biology is projected to grow significantly, Neochromosome faces competition from established players and other startups. Success will depend on securing major partnerships, advancing proprietary tools, and demonstrating scalable commercial applications.

Upcoming Catalysts (preview)

• TBDKey Partnership or Licensing Deal with Pharma or Industrial Biotech60% success
• TBDAnnouncement of Series A or B Funding Round50% success
• TBDLaunch of First Commercial Product or Platform Service40% success